 This is an open-label all people know the identity of the intervention, multicenter when more than one hospital or medical school team work on a medical research study, 2 parts First, dose escalation Phase and second, dose expansion Phase study to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical responses of JNJ-42756493 erdafitinib in Asian participants with advanced HCC. The duration of study will be approximately 11 months per participant. The study consists of 2 periods: Screening 28 days before study commences on Day 1; Open-label Treatment dose escalation portion of the trial Part 1, participants are enrolled into cohorts at increasing dose levels of JNJ-42756493 erdafitinib in 28 day treatment cycles. Part 2, the cohort expansion part of the trial, will further explore the recommended phase 2 dose RP2D of JNJ-42756493 erdafitinib as determined in Part 1; and follow-up Phase up to 6 months. Blood samples will be collected for evaluation of safety, pharmacokinetics, pharmacodynamics, and predictive biomarkers at pre-dose and post-dose of study treatment. Recommended Phase 2 dose RP2D for JNJ-42756493 erdafitinib will be evaluated primarily. Participants safety will be monitored throughout the study. 